牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-043675 Act: 34 Size: 27 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-037453 Act: 34 Size: 28 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-035139 Act: 34 Size: 25 KB 网页链接
$灿菲特生物制药(CANF)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001021 Act: 33 Size: 1 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-031795 Act: 34 Size: 25 KB 网页链接
$灿菲特生物制药(CANF)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001213900-23-031683 Act: 33 Size: 125 KB 网页链接
$灿菲特生物制药(CANF)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001213900-23-031684 Act: 33 Size: 532 KB 网页链接
$灿菲特生物制药(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-23-028391 Act: 34 Size: 23 KB 网页链接
$灿菲特生物制药(CANF)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001213900-23-025511 Act: 33 Size: 521 KB 网页链接
$灿菲特生物制药(CANF)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001213900-23-024298 Act: 34 Size: 8 MB 网页链接